A Single-arm, Phase II Study for Bone Marrow Protection, Safety, and Efficacy of Trilaciclib Combined With Eribulin in Locally Advanced or Metastatic Triple-negative Breast Cancer After at Least Two Prior Chemotherapy Regimens

Triple negative breast cancer (TNBC) has attracted much attention due to its young age of onset, high aggressiveness, lack of clear therapeutic targets and poor clinical prognosis.Eribulin is a novel non-taxane anti-microtubule inhibitor with unique microtubule and non-microtubule anti-tumor mechanism.Myelosuppression is the cause of many cancer chemotherapy-related adverse events, such as infections, sepsis, bleeding, and fatigue, resulting in delayed hospital stays or the need for treatment with hematopoietic growth factors, blood transfusions, and more.In addition, myelosuppression usually leads to a lower dose or longer interval of chemotherapy, which reduces the intensity of chemotherapy and affects the benefit of chemotherapy for patients.Trilaciclib is a highly potent, selective and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy.

开始日期2026-11-04

申办/合作机构

中山大学

NCT07494448

/ Not yet recruiting临床1/2期

PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER

The JAZMINE study is a multicenter, open-label, non-comparative, phase Ib/II clinical trial to evaluate safety and preliminary efficacy of zanidatamab in combination with tucatinib and chemotherapy (capecitabine or eribulin mesylate) in HER2-positive advanced breast cancer.

开始日期2026-07-01

申办/合作机构

Medica Scientia Innovation Research SL

NCT07078604

/ Recruiting临床2期IIT

A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients With Metastatic Triple-Negative Breast Cancer

This phase II trial studies how well a cancer vaccine called STEMVAC works in combination with chemotherapy in treating patients with PD-L1 negative, triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that are expressed on breast cancer stem cells, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. The allowable combination chemotherapy includes: (1) Paclitaxel is in a class of chemotherapy medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. (2) Docetaxel is in a class of chemotherapy medications called taxanes. It stops tumor cells from growing and dividing and may kill them. (3) Cisplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. (4) Carboplatin is in a class of chemotherapy medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. (5) Doxorubicin is in a class of chemotherapy medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. (6) Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. (7) Eribulin is in a class of chemotherapy medications called microtubule dynamics inhibitors. It works by stopping the growth and spread of tumor cells. Giving STEMVAC in combination with chemotherapy may be an effective treatment for PD-L1 negative metastatic triple-negative breast cancer.

开始日期2026-04-11

申办/合作机构

University of Washington

100 项与甲磺酸艾立布林相关的临床结果

登录后查看更多信息

100 项与甲磺酸艾立布林相关的转化医学

登录后查看更多信息

100 项与甲磺酸艾立布林相关的专利（医药）

登录后查看更多信息

1,327

项与甲磺酸艾立布林相关的文献（医药）

2026-05-01·Cancer pathogenesis and therapy

Exploring marine-derived compounds as potential anti-cancer agents: Mechanisms and therapeutic implications

Review

作者: Ekghara, Sumit Dilip ; Bandaru, Nagaraju ; Patil, Yash Pramod ; Patil, Kunal Sharad ; Bonthu, Mohan Gandhi

Marine-derived compounds have emerged as a promising frontier in cancer research due to their remarkable structural diversity and broad-spectrum bioactivities. The marine environment, encompassing diverse organisms (e.g., sponges, algae, tunicates, mollusks, and marine microbes), is a prolific source of novel bioactive molecules with potent anti-cancer properties. Key classes of these compounds include alkaloids, polysaccharides, peptides, terpenoids, and polyketides, which exert anti-tumor effects through diverse mechanisms, including the induction of apoptosis, inhibition of angiogenesis, modulation of immune responses, interference with cell cycle progression, and targeting of critical signaling pathways involved in tumorigenesis and metastasis. Notably, marine-derived drugs such as trabectedin, eribulin, and plitidepsin have received regulatory approval for the treatment of various malignancies, demonstrating the translational potential of these natural compounds. Ongoing clinical and preclinical investigations are exploring a wide range of marine metabolites for their cytotoxic, anti-proliferative, and chemosensitizing properties. Advances in marine biotechnology, including genome mining, synthetic biology, and fermentation technologies, have significantly facilitated the discovery, sustainable production, and structural optimization of marine natural products. However, challenges such as low yield, structural complexity, limited water solubility, and poor bioavailability hinder their broader clinical application. The integration of novel drug delivery systems, such as nanoparticles, liposomes, and conjugates, offers a viable solution to overcome these limitations and improve pharmacokinetic profiles. This review provides a comprehensive overview of the mechanisms of action, therapeutic applications, and clinical development of marine-derived anti-cancer compounds. It also emphasizes the need for deeper insights into their molecular targets and the potential for synergistic use with existing chemotherapeutic agents. Future directions should focus on exploring untapped marine biodiversity, developing eco-friendly harvesting strategies, and developing innovative delivery platforms to fully harness the therapeutic promise of the marine pharmacopeia in oncology.

2026-02-01·Cancer research communications

ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer

Article

作者: Terada, Sayuri ; Higashi, Eika ; Ohashi, Takahiro ; Kawai-Asami, Kayoko ; Yoshimi, Hisashi ; Fukushima, Keiko ; Kuramochi, Mizuki ; Nagasaki, Tsubasa ; Ohshita, Ryuichiro ; Nagata, Yuko ; Todoroki, Mai ; Furuya, Makoto ; Hiramoto, Shinsuke ; Akatsuka, Kotomi

Abstract:

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by a poor prognosis owing to the lack of therapeutic targets, including hormone receptors and HER2. Systemic chemotherapy remains the primary treatment option; however, its efficacy is limited by chemotherapy resistance, a substantial challenge in clinical management. The present study aimed to develop a novel anticancer drug that overcomes chemotherapy resistance in TNBC. First, chemotherapy-resistant MDA-MB-468 cells derived from TNBC were developed via long-term exposure to adriamycin or paclitaxel. Compared with parental cells, these resistant cells exhibited reduced sensitivity to paclitaxel, adriamycin, and eribulin in the viability assays. Various compounds were screened for their cell growth–inhibitory activity against these resistant cells to identify novel therapeutic agents; ZSTK3744 was a promising candidate and showed significant antitumor activity in vitro and in vivo. ZSTK3744 upregulated CYP1A1, CYP1B1, and TIPARP expression in MDA-MB-468 cells but exhibited no cell growth–inhibitory activity in aryl hydrocarbon receptor (AhR)–knockout cells, indicating that ZSTK3744 acts as an AhR agonist. Notably, ZSTK3744 demonstrated superior tumor inhibition and lower pulmonary toxicity in ex vivo and in vivo models than other AhR agonists. These results suggest that ZSTK3744 combines robust cell growth–inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype.

Significance::

ZSTK3744 was identified through screening for its cell growth–inhibitory activity on chemotherapy-resistant TNBC cells. ZSTK3744 exerts its activity through AhR. ZSTK3744 exhibits superior cell growth–inhibitory activity compared with other AhR agonists and demonstrates a favorable safety profile. Therefore, ZSTK3744 is a promising therapeutic agent for overcoming chemotherapy resistance in TNBC.

2026-01-01·European Journal of Hospital Pharmacy

Monitoring of occupational exposure to hazardous medicinal products in robotic compounding

Article

作者: Camba, Yoana ; Tames, Maria Jose ; Ferro Uriguen, Alexander ; Olariaga Sarasola, Olatz ; Asensio Bermejo, Ainhoa ; Urretavizcaya, Mikel ; Riestra, Ana C ; Iglesias, Ainara

OBJECTIVE:

This study aims to evaluate the risk of occupational exposure to hazardous medicinal products (HMPs) when utilising robotic compounding systems for the preparation of antineoplastic sterile medications. Specifically, it assesses the levels of HMPs present on the surfaces of ready-to-use preparations and on the gloves worn by personnel involved in the compounding process.

METHODS:

The study was conducted over three consecutive days during routine production with a robotic compounding system. Each day, wipe samples were collected from the surfaces of 20 HMPs preparations and from the gloves of the operator involved in the compounding process. Analyses were performed using an Ultra-High Performance Liquid Chromatography (UHPLC) system to detect and quantify 25 commonly used anticancer molecules in hospital pharmacies.

RESULTS:

Throughout the study, the robot compounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, eribulin, etoposide, gemcitabine, irinotecan, nivolumab, oxaliplatin, paclitaxel, panitumumab, pembrolizumab, pemetrexed, trastuzumab, and vinorelbine. Only negligible amounts of gemcitabine, below the quantification limit (<0.0025 ng/cm²), were detected on the surfaces of 10 out of the 60 bags and on two of the operator's gloves.

CONCLUSION:

The results demonstrate that surface contamination levels of HMPs in robotic compounding are exceedingly low and, in most cases, undetectable. Occupational exposure to HMPs remains consistently below 0.1 ng/cm², a threshold deemed safe according to various studies. These findings assure the safety of compounding personnel and other hospital staff involved in cancer treatment.

722

项与甲磺酸艾立布林相关的新闻（医药）

2026-03-27

·手机新浪网

博瑞医药涨6.52%，成交额8.85亿元，近5日主力净流入4467.11万

3月27日，博瑞医药涨6.52%，成交额8.85亿元，换手率4.26%，总市值209.52亿元。异动分析细胞免疫治疗+重组蛋白+减肥药+流感+创新药1、根据2025年11月15日公告：极客基因是一家以高通量组学数据调控细胞命运为特色的创新型细胞药物开发公司，主要从事单细胞测序服务以及免疫细胞疗法开发业务，目前聚焦于开发长寿命肿瘤反应性 T 细胞药物用于治疗中晚期实体肿瘤。极客基因拥有世界领先的单细胞多组学数据收集平台、低成本高通量组学技术平台，以及细胞命运重编程技术平台，相关数据的稳定性处于世界领先水平。基于三大技术平台，极客基因开发出细胞命运导航系统，并用于研发创新 T 细胞治疗药物。2、博瑞生物医药(苏州)股份有限公司致力于研发和生产高端仿制药和原创性新药的高科技制药企业。主要从事高技术壁垒的医药中间体、原料药和制剂产品的研发和生产业务。公司的主要产品为抗体药物、疫苗、核酸药物和细胞治疗产品、产业化技术、重组蛋白质药物。3、BGM0504 注射液是公司自主研发的 GLP-1（胰高血糖素样肽 1）和 GIP（葡萄糖依赖性促胰岛素多肽）受体双重激动剂。2022 年 12 月，博瑞新创收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意 BGM0504 注射液开展减重和 2 型糖尿病适应症临床试验。4、2025年1月27日互动易：在国内，公司已取得磷酸奥司他韦胶囊、磷酸奥司他韦干混悬剂生产批文，磷酸奥司他韦原料药与制剂共同审评审批结果为A。磷酸奥司他韦胶囊用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗（磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多）。用于成人和13岁及13岁以上青少年的甲型和乙型流感的预防。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗（磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多）。患者应在首次出现症状48小时以内使用。用于1岁及以上年龄人员的甲型和乙型流感的预防。产能信息情况请以公司公告为准。5、2023年半年报：公司现有抗肿瘤领域的核心产品包括艾立布林、创新药 BGC0228 以及创新药 BGM0504 等。在创新药物研发领域，公司依托偶联药物技术平台以及药械组合平台，致力于孵化出具有高度差异化、较大临床价值及较高商业价值的产品。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入7161.95万，占比0.08%，行业排名11/158，连续3日被主力资金增仓；所属行业主力净流入29.08亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入7161.95万8264.55万4467.11万4.56亿3.96亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额2.07亿，占总成交额的7.39%。技术面：筹码平均交易成本为49.39元该股筹码平均交易成本为49.39元，近期筹码快速出逃，建议调仓换股；目前股价靠近支撑位48.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28栋,香港铜锣湾勿地臣街1号时代广场2座31楼，成立日期2001年10月26日，上市日期2019年11月8日，公司主营业务涉及研发和生产高端仿制药和原创性新药。主营业务收入构成为：原料药-其他类33.36%，原料药-抗真菌类26.16%，制剂类14.40%，技术权益及服务收入9.03%，原料药-免疫抑制类8.57%，原料药-抗病毒类5.70%，其他(补充)2.79%。博瑞医药所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：超级真菌、仿制药一致性评价、仿制药、减肥药、新冠药物等。截至2月28日，博瑞医药股东户数2.01万，较上期减少2.56%；人均流通股21035股，较上期增加2.63%。2025年1月-12月，博瑞医药实现营业收入12.24亿元，同比减少4.59%；归母净利润5451.47万元，同比减少71.18%。分红方面，博瑞医药A股上市后累计派现2.46亿元。近三年，累计派现1.29亿元。机构持仓方面，截止2025年12月31日，博瑞医药十大流通股东中，香港中央结算有限公司位居第六大流通股东，持股471.29万股，相比上期减少400.91万股。南方中证500ETF（510500）位居第七大流通股东，持股450.83万股，为新进股东。创新药（159992）位居第九大流通股东，持股358.27万股，相比上期增加67.18万股。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。

2026-03-27

·ioncology

乳腺癌 ADC 序贯治疗新思路：如何实现跨亚型应用与临床获益最大化

编者按：乳腺癌是全球女性高发的恶性肿瘤，转移性乳腺癌（mBC）的治疗始终是临床攻坚的重点。抗体偶联药物（ADC）的问世，凭借靶向性与细胞毒性的双重优势，彻底重塑了HER2阳性及低表达乳腺癌的治疗格局[1]。其中新型HER2 ADC凭借独特的作用机制，在临床研究和真实世界中展现出显著疗效，而如何通过科学的序贯治疗策略，结合不同ADC药物的特点最大化患者获益，也成为当下临床研究的核心方向。本文将向读者介绍不同亚型乳腺癌的 ADC 序贯治疗现状，剖析新型 HER2 ADC 在序贯治疗中的核心优势，同时梳理优化 ADC 序贯治疗的关键临床策略，为临床个体化用药提供循证医学依据，助力提升转移性乳腺癌患者的治疗获益与生存预后。一、ADC药物：乳腺癌靶向治疗的精准利器 ADC由靶向抗体、连接子和细胞毒性载荷（payload）三部分构成，通过抗体与肿瘤细胞表面特异性抗原的结合，将化疗药物精准递送至肿瘤内部，实现对肿瘤细胞的选择性杀伤，大幅降低对正常组织的损伤[1]。目前国内获批用于乳腺癌的ADC药物中，T-DM1和新型HER2 ADC成为HER2靶向治疗的核心选择。T-DM1以微管抑制剂为载荷，是HER2阳性乳腺癌二线治疗的重要药物[2]；而新型HER2 ADC药物T-DXd搭载拓扑异构酶I抑制剂，不仅在HER2阳性乳腺癌中表现优异，更率先打破了HER2低表达乳腺癌的靶向治疗空白，为这一占乳腺癌总数45%-55%的群体带来了新希望[3]。其独特的旁杀伤效应还能对肿瘤微环境中的异质性肿瘤细胞发挥作用，进一步提升抗肿瘤效果[4]，也为其在序贯治疗中的应用奠定了坚实基础。二、新型HER2 ADC在不同亚型乳腺癌序贯治疗中的核心优势（一）HER2阳性乳腺癌：后线使用仍高效，跨线疗效稳定 HER2阳性乳腺癌患者经一线治疗进展后，二线及后线治疗选择直接影响生存预后，新型HER2 ADC在此领域展现出不可替代的优势。Ⅲ期临床试验DESTINY-Breast02证实，对于既往接受过T-DM1治疗的HER2阳性转移性乳腺癌患者，后续使用新型HER2 ADC T-DXd可获得17.8个月的中位无进展生存期（PFS），显著优于传统化疗方案的6.9个月[5]，充分证明其在T-DM1进展后仍能发挥强效抗肿瘤作用。图1| DEATINY-Breast02研究PFS曲线真实世界研究进一步验证了其跨线疗效稳定性：在409例既往接受过T-DM1治疗的HER2阳性乳腺癌患者队列中，新型HER2 ADC的疗效与未接受过T-DM1治疗的患者相比无显著差异[6]，说明其疗效不受前序T-DM1治疗影响，为临床序贯用药提供了重要真实世界证据。同时，新型HER2 ADC也为反向序贯治疗提供可能，DESTINY-Breast03研究探索性分析显示，患者先使用T-DXd进展后，后续使用T-DM1仍能获得7.6个月的中位治疗持续时间[7]，证实了以其为核心的序贯治疗体系的可行性。（二）HER2低表达乳腺癌：首程使用获益显著，奠定序贯基础 HER2低表达乳腺癌曾因缺乏有效靶向药物长期依赖传统化疗，新型HER2 ADC的获批填补了这一治疗空白。系统分析显示，在HER2低表达转移性乳腺癌患者中，首程使用新型HER2 ADC能获得显著生存获益，中位PFS可达5.1-7.6个月，客观缓解率（ORR）最高可达77.2%[8]，相较传统化疗大幅提升治疗效果，且其疗效在HR阳性和HR阴性的HER2低表达患者中均能稳定体现，不受激素受体状态影响[8]。图2 | ADC1 和 ADC2 在接受或不接受干预治疗时的治疗失败时间（TTF）尽管HER2低表达乳腺癌患者序贯使用ADC药物的疗效会有所下降，但新型HER2 ADC首程使用带来的长PFS和高缓解率，能为患者争取更多治疗时间和后续治疗机会，是该亚型患者序贯治疗的重要基础。同时有研究显示，将新型HER2 ADC作为二线ADC使用时，其PFS也显著优于其他同类药物[9]，进一步证实其在序贯治疗中的独特价值。（三）载荷机制差异：规避交叉耐药，提升序贯疗效交叉耐药是ADC序贯治疗的主要挑战，而载荷机制的差异是规避交叉耐药的核心关键[10]。新型HER2 ADC的载荷为拓扑异构酶I抑制剂，与T-DM1的微管抑制剂载荷机制完全不同，这种非重叠的作用机制使其在序贯治疗中能有效规避交叉耐药，维持抗肿瘤活性。研究显示，相同载荷机制的ADC交叉耐药率达60%，而切换不同机制载荷后，交叉耐药率可降至52.4%[10]，这也是新型HER2 ADC在T-DM1进展后仍能保持高效的重要原因。图：抗体偶联药物（ADCs）相关主要耐药机制的示意图三、优化ADC序贯治疗的关键策略，最大化新型HER2 ADC获益（一）优先选择载荷机制不同的序贯方案基于新型HER2 ADC的载荷机制特点，临床序贯治疗应遵循"不同载荷机制优先"原则。对于HER2阳性乳腺癌，两代不同的ADC药物的序贯方案，已被Ⅲ期临床和真实世界研究证实为高效方案[5,6]，是目前临床推荐的优选策略。对于首程使用新型HER2 ADC的患者，后续也应优先选择载荷机制不同的ADC药物或其他治疗方案，避免使用同类拓扑异构酶I抑制剂的ADC，减少交叉耐药发生，最大程度保留后续治疗有效性。（二）合理应用桥接治疗，为序贯创造条件桥接治疗（两款ADC之间插入传统化疗等非ADC治疗）是优化序贯治疗的重要补充，研究证实，桥接治疗不会降低后续ADC药物的疗效[8,11]，且在部分情况下能为新型HER2 ADC的序贯使用创造更好条件。在793例患者的真实世界研究中，首程ADC治疗后采用紫杉醇、艾立布林等传统化疗作为桥接治疗，相比直接序贯同类载荷的ADC，可显著延长患者PFS（5.9-6.7个月 vs 2.3-2.5个月）[11]。对于HER2低表达乳腺癌患者，首程使用新型HER2 ADC后，合理的桥接治疗能杀伤部分耐药肿瘤细胞，为后续治疗提升效果。（三）动态监测靶点状态，精准把控用药时机靶点表达状态的动态变化是ADC治疗耐药的重要原因，约10%-15%的患者在ADC治疗过程中会出现HER2表达状态改变[12]，而HER2低表达乳腺癌患者因HER2并非主要致癌驱动因子，其表达状态更易在治疗压力下发生下调[13]。因此，在以新型HER2 ADC为核心的序贯治疗中，应重视HER2靶点状态的动态监测：序贯用药前通过肿瘤组织活检或液体活检重新评估HER2表达状态，能精准把控用药时机，避免因靶点表达下调导致的治疗无效，提升序贯治疗的精准性。四、总结与展望新型HER2 ADC凭借独特的作用机制、显著的疗效优势，成为HER2阳性和低表达转移性乳腺癌治疗的核心药物，其在序贯治疗中无论是后线使用的高效性，还是首程使用的奠基作用，都为临床带来了更多治疗可能。遵循"载荷机制不同优先"、合理应用桥接治疗、动态监测靶点状态，能进一步优化新型HER2 ADC的序贯治疗策略，最大化患者获益。未来，随着更多临床研究的开展，新型HER2 ADC与免疫治疗、小分子靶向药物的联合治疗，以及基于生物标志物的个体化序贯方案，将成为研究重点。相信随着对ADC药物作用机制和耐药机制的深入探索，以新型HER2 ADC为核心的精准序贯治疗体系将不断完善，为转移性乳腺癌患者带来更长的生存期和更好的生活质量。参考文献：（滑动查看） [1] Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2022 Mar;72(2):165–82. [2] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 Nov 8;367(19):1783–91. [3] Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022 Jul 7;387(1):9–20. [4] Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Science 2016;107(11):1544-1550. [5] Andrè F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023 May 27;401(10390):1773–85. [6] Tarantino P, Lee D, Foldi J, et al. Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open 2025 Jul 1;10(7). [7] Fasching PA, Bianchini G, Ciruelos EM, et al. Human epidermal growth factor receptor 2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) remain effective in patients (pts) with metastatic breast cancer (mBC): Exploratory analysis from DESTINY-Breast02 and -03. ESMO Open 2025. [8] Huppert LA, Mahtani R, Fisch S, et al. Multicentre retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). npj Breast Cancer 2025 Apr 15;11(1):34. [9] Poumeaud F, Morisseau M, Cabel L, et al. Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study. Cancer Res. 2024 May 2;84(9_Supplement):PS08-02. [10] Abelman RO, Spring L, Fell G, et al. sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. Cancer Res 2024. May 2;84(9_Supplement):PS08-03. [11] Joshi U, Whiting J, Qianxiang M, et al. Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer. Clin Cancer Res 2025 Jun 13;31(12_Supplement):P5–12–08. [12] Morganti S, Tarantino P, Graham N, et al. Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC). ESMO Open 2024;9. [13] Chen W, Gupta A, Mai N, et al. Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. Cancer Discov. 2025 Nov 10. 材料编码：CN-20260327-00010 （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-03-26

·手机新浪网

博瑞医药涨1.88%，成交额6.21亿元，近5日主力净流入-5236.43万

3月26日，博瑞医药涨1.88%，成交额6.21亿元，换手率3.12%，总市值196.70亿元。异动分析细胞免疫治疗+重组蛋白+减肥药+流感+创新药1、根据2025年11月15日公告：极客基因是一家以高通量组学数据调控细胞命运为特色的创新型细胞药物开发公司，主要从事单细胞测序服务以及免疫细胞疗法开发业务，目前聚焦于开发长寿命肿瘤反应性 T 细胞药物用于治疗中晚期实体肿瘤。极客基因拥有世界领先的单细胞多组学数据收集平台、低成本高通量组学技术平台，以及细胞命运重编程技术平台，相关数据的稳定性处于世界领先水平。基于三大技术平台，极客基因开发出细胞命运导航系统，并用于研发创新 T 细胞治疗药物。2、博瑞生物医药(苏州)股份有限公司致力于研发和生产高端仿制药和原创性新药的高科技制药企业。主要从事高技术壁垒的医药中间体、原料药和制剂产品的研发和生产业务。公司的主要产品为抗体药物、疫苗、核酸药物和细胞治疗产品、产业化技术、重组蛋白质药物。3、BGM0504 注射液是公司自主研发的 GLP-1（胰高血糖素样肽 1）和 GIP（葡萄糖依赖性促胰岛素多肽）受体双重激动剂。2022 年 12 月，博瑞新创收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意 BGM0504 注射液开展减重和 2 型糖尿病适应症临床试验。4、2025年1月27日互动易：在国内，公司已取得磷酸奥司他韦胶囊、磷酸奥司他韦干混悬剂生产批文，磷酸奥司他韦原料药与制剂共同审评审批结果为A。磷酸奥司他韦胶囊用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗（磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多）。用于成人和13岁及13岁以上青少年的甲型和乙型流感的预防。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗（磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多）。患者应在首次出现症状48小时以内使用。用于1岁及以上年龄人员的甲型和乙型流感的预防。产能信息情况请以公司公告为准。5、2023年半年报：公司现有抗肿瘤领域的核心产品包括艾立布林、创新药 BGC0228 以及创新药 BGM0504 等。在创新药物研发领域，公司依托偶联药物技术平台以及药械组合平台，致力于孵化出具有高度差异化、较大临床价值及较高商业价值的产品。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入694.22万，占比0.01%，行业排名18/158，连续2日被主力资金增仓；所属行业主力净流入-7.19亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入694.22万-2024.91万-5236.43万4.23亿3.66亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额1.61亿，占总成交额的5.91%。技术面：筹码平均交易成本为49.62元该股筹码平均交易成本为49.62元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位46.95，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28栋,香港铜锣湾勿地臣街1号时代广场2座31楼，成立日期2001年10月26日，上市日期2019年11月8日，公司主营业务涉及研发和生产高端仿制药和原创性新药。主营业务收入构成为：原料药-其他类33.36%，原料药-抗真菌类26.16%，制剂类14.40%，技术权益及服务收入9.03%，原料药-免疫抑制类8.57%，原料药-抗病毒类5.70%，其他(补充)2.79%。博瑞医药所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：超级真菌、仿制药一致性评价、仿制药、减肥药、新冠药物等。截至2月28日，博瑞医药股东户数2.01万，较上期减少2.56%；人均流通股21035股，较上期增加2.63%。2025年1月-12月，博瑞医药实现营业收入12.24亿元，同比减少4.59%；归母净利润5451.47万元，同比减少71.18%。分红方面，博瑞医药A股上市后累计派现2.46亿元。近三年，累计派现1.29亿元。机构持仓方面，截止2025年12月31日，博瑞医药十大流通股东中，香港中央结算有限公司位居第六大流通股东，持股471.29万股，相比上期减少400.91万股。南方中证500ETF（510500）位居第七大流通股东，持股450.83万股，为新进股东。创新药（159992）位居第九大流通股东，持股358.27万股，相比上期增加67.18万股。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。

100 项与甲磺酸艾立布林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08914	甲磺酸艾立布林	L01XX41	DB08871

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肉瘤	日本	Eisai Co., Ltd.	2016-02-29
软组织肿瘤	日本	Eisai Co., Ltd.	2016-02-29
乳腺癌	日本	Eisai Co., Ltd.	2011-04-22
脂肪肉瘤	欧盟	Eisai GmbH	2011-03-17
脂肪肉瘤	冰岛	Eisai GmbH	2011-03-17
脂肪肉瘤	列支敦士登	Eisai GmbH	2011-03-17
脂肪肉瘤	挪威	Eisai GmbH	2011-03-17
局部晚期乳腺癌	欧盟	Eisai GmbH	2011-03-17
局部晚期乳腺癌	冰岛	Eisai GmbH	2011-03-17
局部晚期乳腺癌	列支敦士登	Eisai GmbH	2011-03-17
局部晚期乳腺癌	挪威	Eisai GmbH	2011-03-17
转移性乳腺癌	美国	Eisai, Inc.	2010-11-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	临床3期	日本	Eisai Co., Ltd.	2017-08-28
HER2 阴性乳腺癌	临床3期	中国	Eisai Co., Ltd.	2013-09-26
三阴性乳腺癌	临床3期	中国	Eisai Co., Ltd.	2013-09-26
晚期非小细胞肺癌	临床3期	德国	Eisai Ltd. (Canada)	2011-09-28
晚期非小细胞肺癌	临床3期	意大利	Eisai Ltd. (Canada)	2011-09-28
X联锁鱼鳞病	临床3期	捷克	Eisai Ltd. (Canada)	2011-04-28
局部晚期软组织肉瘤	临床3期	美国	Eisai, Inc.	2011-03-10
局部晚期软组织肉瘤	临床3期	阿根廷	Eisai, Inc.	2011-03-10
局部晚期软组织肉瘤	临床3期	澳大利亚	Eisai, Inc.	2011-03-10
局部晚期软组织肉瘤	临床3期	奥地利	Eisai, Inc.	2011-03-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04579224 (SWOG S1937, ASCO_GU2026)	临床3期	转移性尿路上皮癌	184	Eribulin + Gemcitabine	糧網築鑰顧廠糧鹽繭膚(膚餘簾襯窪憲繭鏇製築) = 構遞網顧蓋膚鹽網顧窪願廠構鬱醖範選憲獵鏇 (醖範醖願鏇淵遞選蓋憲 )	积极	2026-02-26
NCT01676818 (CTgov)	临床2期	复发性宫颈癌	32	eribulin mesylate	膚夢網餘夢鏇廠鏇鹹網(觸鑰膚膚壓簾鹹窪壓窪) = 願遞窪糧網簾繭願觸艱遞窪齋壓製憲遞顧蓋鬱 (鑰夢窪製憲窪醖顧鬱積, 廠鑰膚鏇鏇糧壓衊積鏇 ~ 簾簾鏇鏇衊鏇膚遞鬱繭) 更多	-	2025-11-06
ESMO2025 人工标引	N/A	平滑肌肉瘤 \| 晚期脂肪肉瘤	22	EribulinEribulin + Anlotinib	顧膚範觸製膚顧願夢淵(鑰選鏇廠顧廠夢願鏇選) = 壓獵襯餘鹽糧淵齋蓋憲築鏇齋構蓋壓齋餘夢壓 (網觸齋製選窪網網糧選, 0.6 ~ 14) 更多	积极	2025-10-17
				EribulinEribulin + Anlotinib (LMS)	顧膚範觸製膚顧願夢淵(鑰選鏇廠顧廠夢願鏇選) = 鏇壓廠壓選淵夢衊鏇淵築鏇齋構蓋壓齋餘夢壓 (網觸齋製選窪網網糧選, 2.0 ~ 4.8) 更多
ESMO2025	N/A	晚期乳腺癌	182	Eribulin combined with anti-angiogenesis agents	襯糧窪醖願夢製鹹簾蓋(糧鏇壓憲網願襯糧積範) = leukopenia (53.84%) and neutropenia (65.93%). Three patients experienced grade 4 thrombocytopenia (1.65%). 構壓遞齋構鬱襯築壓夢 (膚鏇簾選鏇餘醖範窪構 ) 更多	积极	2025-10-17
				Eribulin combined with anti-HER2 agents
NCT02623972 (Pubmed \| Breast Cancer Res)	临床2期	HER2 阴性乳腺癌新辅助 hormone receptor-positive	22	Eribulin -> AC	簾鑰窪願淵艱選選醖鑰(憲觸獵構獵餘衊鏇鹹醖) = 鬱鬱齋艱築選簾觸壓簾選憲觸壓鏇鹽構齋鹹醖 (夢遞獵鬱願窪蓋醖製醖 ) 更多	积极	2025-09-29
NCT02061085 (MERIBEL, CTgov)	临床2期	-	53	eribulin	鑰遞鑰顧夢獵蓋鏇獵遞(獵艱醖鏇願窪齋糧築壓) = 憲顧網齋膚鬱選蓋簾鑰鬱獵鑰觸願醖齋網網選 (鏇襯顧觸範遞蓋構網壓, 窪築餘餘醖夢構獵築夢 ~ 齋蓋襯餘艱顧選窪網簾) 更多	-	2025-06-08
ChiCTR2300067650 (ERAS, ASCO2025)	临床2期	局部晚期软组织肉瘤维持 lipid metabolism	30	Eribulin plus Anlotinib	遞鬱構衊餘壓憲鏇製鑰(願觸鬱鹹獵糧壓淵鏇餘) = 範觸鹹蓋糧積廠廠願鬱糧網衊鏇積獵選衊齋範 (製夢衊積網顧糧壓選積 ) 更多	积极	2025-05-30
				Anlotinib monotherapy	遞鬱構衊餘壓憲鏇製鑰(願觸鬱鹹獵糧壓淵鏇餘) = 糧窪餘膚蓋夢憲鹹廠網糧網衊鏇積獵選衊齋範 (製夢衊積網顧糧壓選積 ) 更多
ChiCTR2000038832 (EPIC trial, ASCO2025)	临床2期	晚期 HER2 阳性乳腺癌 HER2-positive	30	Eribulin plus Pyrotinib	鏇觸鏇簾蓋範繭壓窪壓(獵積蓋構獵壓網憲衊蓋) = 觸網願襯壓築糧顧膚網夢淵願壓繭餘齋鑰窪獵 (鹹鹽夢夢鏇簾製憲鬱構, 44.2% ~ 86.0) 更多	积极	2025-05-30
ASCO2025	N/A	HER2阳性乳腺癌新辅助 \| 辅助	3,300	Trastuzumab-pertuzumab combined with taxanes	艱積鏇憲蓋簾顧壓觸衊(糧膚積鏇窪願鹹壓遞鑰) = 製衊願繭構顧繭齋夢膚鑰蓋積遞願選網積選壓 (顧網廠網遞齋製醖鹽願, 14.52 ~ 21.32)	-	2025-05-30
				Trastuzumab-pertuzumab combined with eribulin	繭範鹽築觸蓋積願膚鬱(憲夢繭築鹽膚憲憲齋齋) = 憲夢齋憲範淵繭繭窪鬱壓憲膚衊衊糧遞鏇網遞 (醖壓窪襯壓選獵鹽衊選, 0.65 ~ 0.85)
JBCRG-22 (ESMO_BC2025)	N/A	三阴性乳腺癌新辅助 homologous recombination deficiency \| germline BRCA mutation	99	Paclitaxel + Carboplatin	醖壓衊顧願壓鬱壓獵餘(築鹹餘簾製壓壓鹹憲膚) = 選繭憲膚選醖鹽築淵範壓築餘齋淵淵憲鏇鑰觸 (壓積遞艱鑰壓積鑰齋鬱, 78.8 ~ 100) 更多	积极	2025-05-14
				Eribulin + Carboplatin + Anthracycline	醖壓衊顧願壓鬱壓獵餘(築鹹餘簾製壓壓鹹憲膚) = 鹹壓網築築築衊選構膚壓築餘齋淵淵憲鏇鑰觸 (壓積遞艱鑰壓積鑰齋鬱, 79.7 ~ 100) 更多